| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8163235678eb731fd7107761bee002d8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-01003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-443 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2016-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0e59654b768531cef66af83fca5ce7 |
| publicationDate |
2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180094883-A |
| titleOfInvention |
Macrophage differentiation and transformation method of immunity |
| abstract |
Providing a genetically modified macrophage or mononuclear cell comprising a nucleic acid sequence encoding a fragment thereof comprising a Hom-1 polypeptide or a Hom-1 homeobox domain, wherein the nucleic acid sequence is heterologous wherein the mutated macrophage or mononuclear cell is operably linked to a heterologous promoter, wherein the mutated macrophage or mononuclear cell expresses a Hom-1 polypeptide or fragment thereof; And administering the mutated macrophages or mononuclear cells to a subject having cancer; ≪ / RTI > |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102268963-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023043278-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021010698-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102511633-B1 |
| priorityDate |
2015-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |